ANG1005

Cat. No.:	HY-P4073
CAS No.:	1075214-55-9
Molecular Formula:	$C_{257}H_{308}N_{32}O_{79}$
Molecular Weight:	5109.36
Sequence:	{Paclitaxel-Thr}-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-{Paclitaxel-Lys}-Arg-Asn-Asn-Phe-{Paclitaxel-Lys}-Thr-Glu-Glu-Tyr
Sequence Shortening:	{Paclitaxel-T}FFYGGSRG{Paclitaxel-K}RNNF{Paclitaxel-K}TEEY
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ANG1005

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (19.57 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.1957 mL	0.9786 mL	1.9572 mL
	5 mM	0.0391 mL	0.1957 mL	0.3914 mL
	10 mM	0.0196 mL	0.0979 mL	0.1957 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system[1][2][3].

In Vivo

ANG1005 shows significantly improved delivery to brain and brain metastases of breast cancer compared to free paclitaxel (HY-B0015)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486-94.

[2]. Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3.

[3]. Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA